Register for OBR daily

Kantar Health Conference Sidebar

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CBMG $26.17 4.6001 +21.33%
GALT $15.32 1.6000 +11.66%
IMNP $4.01 0.3100 +8.38%
SNSS $6.70 0.3200 +5.02%
AVEO $1.25 0.0400 +3.31%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PBYI $200.68 -12.2400 -5.75%
Kite $22.02 -1.3400 -5.74%
TGTX $8.44 -0.4800 -5.38%
TSRO $28.26 -1.5600 -5.23%
ARIA $5.89 -0.2930 -4.74%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

European CHMP Adopts Positive Opinion for Gilead's Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

(MarketWatch) July 25, 2014 - Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Zydelig® (idelalisib).
read article 

Head of Troubled CDC Anthrax Lab Resigns

(USA Today) July 23, 2014 - A series of embarrassing and serious safety incidents at the Centers for Disease Control and Prevention has resulted in the resignation of a top laboratory official in Atlanta.
read article 

Tests Suggest Limits to Vertex’s Cystic Fibrosis Treatment

(Boston Globe) July 24, 2014 - Two teams of scientists showed that the medications in the two-drug regimen interfere with each other.
read article (free registration required) 

GSK Seeks Approval For World's First Malaria Vaccine

(Reuters) July 24, 2014 – GlaxoSmithKline said on Thursday it is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.
read article 

FDA Warns of Compounded Drug Recall by Texas Firm

(New York Times/Associated Press) July 23, 2014 - The Food and Drug Administration warned doctors Wednesday not to use compounded drugs from a Texas specialty pharmacy due to potential risks of contamination.
read article 

Specialty Drugs Transform Lives — But at a Cost

(Boston Globe) July 21, 2014 - Expensive new specialty drugs offer hope to patients with rare and chronic illnesses — but also leave many worrying about paying for them.
read article (free registration required) 

Gilead’s Hepatitis C Drug, Sovaldi, Is on Pace to Become a Blockbuster

(New York Times) July 23, 2014 – Sales of Sovaldi reached $3.5 billion in the second quarter, testifying to the effectiveness of the drug, which can essentially cure over 80 percent of patients with few side effects.
read article 

Nonprofit Kicks Off National Bus Tour to Collect Words of Comfort for Cancer Patients

(Yahoo! Finance) July 24, 2014 - Giving Comfort – a program of the McKesson Foundation that provides care packages called "Comfort Kits" to low-income cancer patients – today launched its first ever cross-country bus tour to promote Words of Comfort.
read article 

21st Century Cures: ASCO Supports Congressional Effort to Accelerate Medical Progress

(ASCO in Action) July 23, 2014 - ASCO is participating in the House Energy and Commerce Committee examination of the pace of medical progress in the United States.
read article 

Lion Biotechnologies Leases New Research Laboratory

(CNN Money) July 23, 2014 - Facility to focus on development of next-generation TIL technologies.
read article 

BloodCenter Develops Blood Disorder Test

( July 23, 2014 - BloodCenter of Wisconsin’s Diagnostic Laboratories now offers a Calreticulin mutation analysis, which identifies gene mutations that are present in patients with rare and chronic blood disorders.
read article 

Onco360® Named To Zydelig® (idelalisib) Limited Distribution Network; Just Approved Zydelig Is Available Immediately For Order Through Onco360

(Onco360) July 23, 2014 – Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, today announced that it has been selected to be part of the highly limited Specialty Pharmacy network of Zydelig (idelalisib) tablets.
read corporate press release 

Zeltia Looks at Aplidin Combo For Multiple Myeloma

(PharmaTimes [UK]) July 23, 2014 - Zeltia has expanded the clinical programme for its investigational multiple myeloma treatment Aplidin.
read article 

Puma Shares Soar When Wall Street Misplays Expectation Game

(TheStreet) July 23, 2014 - Puma is why so many investors love to speculate on biotech stocks. A contrarian trade against a heavily expected outcome can return a fortune.
read article 

Bristol-Myers Enters Into Immuno-Oncology Collaboration With Ono Pharmaceutical

(Pharmaceutical Business Review) July 24, 2014 - Bristol-Myers Squibb and Ono Pharmaceutical have entered into a strategic agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens for cancer patients in Japan, South Korea and Taiwan.
read article 

Celsion Announces Positive Interim Data Update From Its Phase 2 DIGNITY Study in Breast Cancer

(MarketWatch) July 24, 2014 - Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC).
read article 

Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP

(San Francisco Business Times) July 24, 2014 - Lpath, Inc. reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all.
read article 

Good Odds for Those Who Need Bone Marrow Donor, Study Finds

(U.S. News & World Report/HealthDay News) July 23, 2014 - Most blood cancer patients in the United States who need a bone marrow transplant can find an acceptable match through the National Marrow Donor Program, a new study has determined.
read article 

Metastatic Brain Tumor Treatment Could Be on the Horizon With SapC-DOPS Use

(University of Cincinnati) July 24, 2014 - Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases.
read press release 

Statin Use Decreases the Risk of Barrett's Esophagus

(AGA) July 23, 2014 - Statins, a class of drugs commonly used to lower cholesterol levels, significantly reduce a patient’s risk of developing Barrett’s esophagus, according to a new study in Gastroenterology.
read press release 

UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients

(UPMC) July 24, 2014 – The routine use of a molecular testing panel developed at UPMC greatly increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer, report researchers from the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter.
read press release 

Research Led by Temple's Chair of Dermatology Shows that Pain and Itch May Be Signs of Skin Cancer

(Temple Health) July 23, 2014 - Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely to be cancerous, according to a new study at Temple University School of Medicine.
read press release 

Sunitinib or Everolimus First-Line for Kidney Cancer?

(Medscape Medical News) July 24, 2014 - A phase 2 randomized comparator trial has found that first-line everolimus is not as effective as first-line sunitinib, and has a different toxicity profile.
read article (free registration required) 

Surgical Robot Fails to Show Advantages in Treating Bladder Cancer

(Wall Street Journal) July 23, 2014 - A new study finds treating bladder cancer with a surgical robot made by Intuitive Surgical is no better at reducing procedural complications than performing the procedure with traditional surgery, a result that surprised researchers, who had expected the robotic technology to be superior to human hands alone.
read article (paid subscription required) 

New View of Stomach Cancer Could Hasten Better Therapies

(Dana-Farber) July 23, 2014 - In a massive effort to catalog the molecular causes of stomach cancer, scientists, including researchers from Dana-Farber Cancer Institute, have identified four subtypes of tumors based on shared mutations and other molecular abnormalities.
read press release